Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1163 in moderately-to-severely active rheumatoid arthritis
NCT07276581Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 2 trial of AZD1163 in rheumatoid arthritis (RA), sponsored by AstraZeneca. Started Dec 2025; status: recruiting.
02
Drugs
AZD1163
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07276581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276581.